C-reactive protein, atherosclerosis and kidney function in hypertensive patients

M J Hommels1, A J A M van der Ven, A A Kroon

  • 1Department of Medicine, University Hospital Maastricht, The Netherlands.

Insights

High-sensitivity C-reactive protein (hsCRP) levels are higher in patients with atherosclerosis in the aorta and renal arteries. This suggests a link between inflammation and vascular disease, though renal function also plays a role.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Inflammation Biology

Background:

  • Previous research links C-reactive protein (CRP) to coronary and carotid atherosclerosis.
  • High-sensitivity CRP (hsCRP) is a marker of systemic inflammation.
  • Atherosclerosis affects major arteries, including those supplying the kidneys.

Purpose of the Study:

  • To investigate the association between hsCRP levels and atherosclerotic lesions in the renal arteries and abdominal aorta.
  • To determine if hsCRP is a marker for atherosclerotic renovascular disease.
  • To explore potential confounding factors in the hsCRP-atherosclerosis relationship.

Main Methods:

  • Prospective study involving 95 hypertensive patients undergoing digital subtraction angiography (DSA) for suspected renovascular disease.
  • Blood samples collected during DSA for hsCRP measurement.
  • Assessment of atherosclerotic lesions in renal arteries and abdominal aorta; renal artery stenosis defined as ≥50%.

Main Results:

  • Median hsCRP concentrations were significantly higher in patients with aortic/renal artery atherosclerosis (4.6 mg/l) compared to those without (1.7 mg/l; P < 0.005).
  • hsCRP levels were elevated in patients with >50% renal artery stenosis.
  • Associations were confounded by serum creatinine, creatinine clearance, age, and gender; an inverse relationship between creatinine clearance and hsCRP was observed (P < 0.05).

Conclusions:

  • hsCRP concentrations are associated with atherosclerotic lesions in the renal arteries and abdominal aorta.
  • Atherosclerotic renal artery stenosis may be part of a systemic inflammatory vascular disease.
  • Elevated hsCRP may also be linked to impaired renal function.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...